Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc (NASDAQ:PCVX) estimates it will grow to ~$12 billion in the next few years.
全球市场研究肺炎球菌偶联物（PCV）市场每年约为80亿美元，Vaxcyte Inc（纳斯达克股票代码：PCVX）估计，未来几年该市场将增长至约120亿美元。
The market is currently split into 25% adults / 75% infants. Needham writes that Vaxcyte's management expects this split to morph into 60% adults /40% infants over the next 3-5 years, with adults representing the bulk of the growth opportunity.
目前，该市场分为25％的成人/ 75％的婴儿。尼德姆写道，Vaxcyte的管理层预计，在未来3-5年中，这种比例将演变为60％的成年人/40％的婴儿，其中成年人占增长机会的大部分。
In the U.S., there's discussion about lowering the age for vaccinations to 50 and above, potentially doubling the adult market. With around 60 million adults aged 65 and above and approximately 120 million aged 50 and above, this shift could significantly impact the market.
在美国，有人讨论将疫苗接种年龄降低到50岁及以上，这可能会使成人市场翻一番。大约有6000万65岁及以上的成年人和大约1.2亿50岁及以上的成年人，这种转变可能会对市场产生重大影响。
Additionally, there's potential for the universal vaccination age to decrease, creating an opportunity for boosters in the adult market.
此外，普及疫苗接种年龄有可能降低，这为成人市场的强化疫苗创造了机会。
Merck & Co Inc's (NYSE:MRK) 15-valent (Vaxneuvance) and Pfizer Inc's (NYSE:PFE) 20-valent (Prevnar20) are the available pneumococcal conjugate vaccines (PCVs).
默沙东公司（纽约证券交易所代码：MRK）的15价（Vaxneuvance）和辉瑞公司（纽约证券交易所代码：PFE）的20价（Prevnar20）是可用的肺炎球菌偶联疫苗（PCV）。
Needham maintains the Buy rating with a price target of $95.
尼德姆维持买入评级，目标股价为95美元。
Market adoption is driven by vaccine coverage, with Prevnar20 currently dominating with a 97% market share in adults due to its broader valency. Merck's 15-valent and Pfizer's 20-valent PCVs are accessible for infants, with Merck initially targeting this market.
疫苗覆盖率推动了市场的采用，Prevnar20由于其价值更广，目前在成人中占据主导地位，其市场份额为97％。默沙东的15价和辉瑞的20价多氯联苯可供婴儿使用，默沙东最初的目标是这个市场。
However, Prevnar20 is expected to capture the majority of the infant market as well.
但是，预计Prevnar20也将占领大部分婴儿市场。
Needham highlights that Pfizer, Merck, and Sanofi SA (NASDAQ:SNY) are currently limited to the 20/21 conjugate level in their vaccine development. However, Vaxcyte stands out with the capability to reach up to 24 conjugates, leading to a stronger immune response.
尼德姆强调，辉瑞、默沙东和赛诺菲公司（纳斯达克股票代码：SNY）目前在疫苗开发中仅限于20/21偶联物水平。但是，Vaxcyte脱颖而出，能够达到多达24种偶联物，从而增强免疫反应。
Vaxcyte also has a 31-valent vaccine. Regarding Merck's V116, Vaxcyte predicts its approval but doubts it will receive the preferred ACIP recommendation.
Vaxcyte 还有 31 价疫苗。关于默克的V116，Vaxcyte预计会获得批准，但怀疑它能否获得首选的ACIP建议。
Price Action: PCVX shares are down 4.03% at $61.91 on the last check Wednesday.
价格走势：在周三的最后一次支票中，PCVX股价下跌4.03％，至61.91美元。
Photo via Shutterstock
照片来自 Shutterstock